Ticker > Company >

Solara Active Pharma share price

Solara Active Pharma Sciences Ltd.

NSE: SOLARA BSE: 541540 SECTOR: Pharmaceuticals & Drugs  70.18 K   150   26

663.30
-1.00 (-0.15%)
BSE: 05 Sep 04:01 PM

Price Summary

Today's High

₹ 680

Today's Low

₹ 657.85

52 Week High

₹ 885.95

52 Week Low

₹ 441.1

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3193.99 Cr.

Enterprise Value

3966.08 Cr.

No. of Shares

4.82 Cr.

P/E

146.72

P/B

2.87

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  230.8

CASH

3.97 Cr.

DEBT

776.06 Cr.

Promoter Holding

42.01 %

EPS (TTM)

₹  4.52

Sales Growth

-0.4%

ROE

-0.11 %

ROCE

5.97%

Profit Growth

99.81 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.4%
3 Year0.4%
5 Year-0.58%

Profit Growth

1 Year99.81%
3 Year25.6%
5 Year-139.49%

ROE%

1 Year-0.11%
3 Year-16.03%
5 Year-6.94%

ROCE %

1 Year5.97%
3 Year-3.15%
5 Year1.03%

Debt/Equity

0.7101

Price to Cash Flow

15.01

Interest Cover Ratio

0.9906

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 42.01 38.95
Mar 2025 37.94 34.64
Dec 2024 37.23 40.74
Sep 2024 37.27 38.00
Jun 2024 37.27 38.28
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 25.6036376573574% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 32.36 days.

 Limitations

  • The company has shown a poor revenue growth of 0.403618761789648% for the Past 3 years.
  • Company has a poor ROE of -16.0263666666667% over the past 3 years.
  • Promoter pledging has increased from 34.6352787826593% to 38.95% in 1 quarter.
  • Company has a poor ROCE of -3.15216666666667% over the past 3 years
  • Company has low Interest coverage ratio of 0.9906.
  • Tax rate is low at 0.
  • Promoter pledging is high as 38.95%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 363.49 346.95 300.31 273.01 319.15
Total Expenditure 321.25 285.63 242.62 230.42 262.12
Operating Profit 42.24 61.32 57.69 42.59 57.03
Other Income 1.38 0.32 1.49 5.95 0.98
Interest 30.87 28.28 26.54 29.12 23.9
Depreciation 25.07 25.34 24.54 24.3 23.58
Exceptional Items 0 0 0 0 0
Profit Before Tax -12.32 8.02 8.1 -4.88 10.53
Tax 0 0 0 0 0
Profit After Tax -12.32 8.02 8.1 -4.88 10.53
Adjusted EPS (Rs) -3.06 1.99 2.01 -1.21 2.37

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1616.88 1268.34 1443.81 1288.92 1283.76
Total Expenditure 1231.55 1187.99 1309.77 1383.98 1079.92
Operating Profit 385.33 80.35 134.04 -95.06 203.84
Other Income 28.41 18.76 22.14 5.37 9.14
Interest 84.47 75.27 90.06 105.97 114.81
Depreciation 108.31 112.01 110.9 103.03 99.25
Exceptional Items 0 -3.49 0 -189.64 0
Profit Before Tax 220.96 -91.66 -44.78 -488.33 -1.08
Tax 0 -33.1 -22.57 78.54 0
Net Profit 220.96 -58.56 -22.21 -566.87 -1.08
Adjusted EPS (Rs.) 56.68 -14.99 -5.69 -145.13 -0.27

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 35.93 36 36 36 40.25
Total Reserves 1556.86 1491.05 1467.13 901.42 1055.96
Borrowings 154.83 283.04 235.1 105.83 113.86
Other N/C liabilities 51.7 16.18 -17.94 65.7 76.96
Current liabilities 785.3 1056.03 1096.12 1237.65 938.07
Total Liabilities 2584.62 2882.3 2816.41 2346.6 2225.1
Assets
Net Block 1349.49 1325 1333.22 1258.7 1184.52
Capital WIP 87.72 238.65 238.47 256.37 280.05
Intangible WIP 0 0 0 0 0
Investments 18.13 14.77 16.05 14.25 1.7
Loans & Advances 60.6 54.38 28.5 23.76 27.52
Other N/C Assets 10.69 9.63 9.3 2.87 2.71
Current Assets 1057.99 1239.87 1190.87 790.65 728.6
Total Assets 2584.62 2882.3 2816.41 2346.6 2225.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 220.96 -91.66 -44.78 -488.33 -1.08
Adjustment 173.16 181.98 186.88 405.79 212.16
Changes in Assets & Liabilities -207.11 -314.04 0.36 192.57 2.62
Tax Paid -32.57 -18.05 13.71 0.92 -0.9
Operating Cash Flow 154.44 -241.77 156.17 110.95 212.8
Investing Cash Flow -105.25 -243.08 -81.13 -4.66 -36.83
Financing Cash Flow 92.5 333.59 -112.76 -106.52 -180.48
Net Cash Flow 141.69 -151.26 -37.72 -0.23 -4.51

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 37.27 37.27 37.23 37.94 42.01
aditya arun kumar 0.11 0.11 0.11 0.11 0.11
agnus capital llp 1.77 1.77 1.77 1.77 1.76
agraganya private trust 1.09 1.09 1.09 1.09 1.09
arunkumar pillai - - - - 3.46
chayadeep properties priv... - 1.10 1.09 1.09 1.09
chayadeep ventures llp 2.11 2.11 2.11 2.11 2.10
deepa arun kumar 0.12 0.12 0.12 0.12 0.12
devicam capital llp . - - - - 15.50
hemalatha pillai 0.10 0.10 0.10 0.10 0.10
k r lakshmi 0.06 0.06 0.06 0.06 0.06
k r ravishankar 2.76 2.76 2.76 2.76 2.75
karuna business solutions... 0.14 0.14 0.14 0.14 0.14
karuna ventures private l... 0.02 0.02 0.02 0.02 0.02
padmakumar karunakaran pi... 0.11 0.11 0.11 0.11 0.11
pronomz ventures llp 4.86 4.86 4.85 5.57 9.71
rajitha gopalakrishnan 0.06 0.06 0.06 0.06 0.06
sajitha pillai 0.11 0.11 0.11 0.11 0.11
srjr enterprise llp 3.54 3.54 3.54 3.54 3.53
tarini arun kumar 0.11 0.11 0.11 0.11 0.11
vineetha mohanakumar pill... 0.07 0.07 0.07 0.07 0.07
arunkumar pillai 3.48 3.48 3.47 3.47 -
devicam capital llp 15.55 15.55 15.53 15.53 -
chayadeep properties pvt ... 1.10 - - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 62.73 62.73 62.77 62.06 57.99
aditya birla sun life tru... - - - - 1.18
authum investment and inf... - 4.27 3.80 3.80 3.79
caisse de depot et placem... 2.37 - - 1.92 1.73
fssa indian subcontinent ... - - - - 1.87
hbm healthcare investment... 2.18 2.18 2.18 2.18 2.17
investor education and pr... 0.02 0.02 - 0.02 0.02
llp - 8.54 8.52 8.37 4.20
raptakos, brett and co. l... - - - - 1.38
route one offshore master... 1.45 1.45 1.45 1.45 1.45
spiracca ventures llp . - - - - 3.55
the scottish oriental sma... 2.92 2.83 2.54 2.54 2.38
tpg growth iv sf pte. ltd... 8.60 4.44 2.87 2.61 2.61
turnaround opportunities ... 1.06 1.19 1.15 1.01 1.01
aditya birla sun life tru... - - - 1.28 -
fssa indian subcontinent ... 2.40 - - 2.04 -
raptakos brett & co limit... 1.39 1.39 1.38 1.38 -
spiracca ventures llp . - 7.79 7.78 7.72 -
aditya birla sun life tru... 1.28 1.28 1.28 - -
caisse de depot et placem... - 2.26 1.92 - -
fssa indian subcontinent ... - 2.37 2.04 - -
investor education and pr... - - 0.02 - -
spiracca ventures llp 7.79 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY22
Concall Q3FY24
Concall Q3FY22
Concall Q2FY24
Concall Q1FY24
Concall Q1FY24
Concall Q1FY23
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY22
Presentation Q4FY21
Presentation Q3FY25
Presentation Q2FY22
Presentation Q2FY21
Presentation Q2FY20
Presentation Q1FY21

Company News

Solara Active Pharma Sciences informs about receipt of call money 16 Aug, 2:52 PM Solara Active Pharma Sciences informs about press release 25 Jul, 5:11 PM Solara Active Pharma - Quaterly Results 25 Jul, 1:23 PM Solara Active Pharma - Quaterly Results 25 Jul, 1:23 PM Solara Active Pharma - Quaterly Results 25 Jul, 1:23 PM Solara Active Pharma - Quaterly Results 15 May, 2:24 PM Solara Active Pharma - Quaterly Results 15 May, 2:24 PM Solara Active Pharma - Quaterly Results 15 May, 2:24 PM USFDA concludes inspection at Solara’s Ambernath facility 10 May, 4:54 PM Solara Active Pharma Sciences submits board meeting intimation 7 May, 4:33 PM Solara Active Pharma informs about outcome of board meeting 6 May, 4:16 PM Solara Active Pharma Sciences informs about shifting of registered office 5 May, 5:32 PM Solara Active Pharma Sciences incorporates wholly-owned subsidiary 30 Apr, 9:19 AM Solara Active Pharma Sciences informs about certificate 17 Apr, 5:23 PM Solara Active Pharma Sciences informs about proposed incorporation of WOS 7 Feb, 3:17 PM Solara Active Pharma Sciences informs about earnings call transcript 31 Jan, 4:59 PM Solara Active Pharma Sciences informs about integrated filing 29 Jan, 5:28 PM Solara Active Pharma - Quaterly Results 24 Jan, 2:46 PM Solara Active Pharma - Quaterly Results 24 Jan, 2:46 PM Solara Active Pharma - Quaterly Results 24 Jan, 2:46 PM Solara Active Pharma Sciences informs about board meeting 16 Jan, 3:17 PM Solara Active Pharma Sciences informs about conference call 16 Jan, 12:29 PM Solara Active Pharma Sciences informs about disclosure 24 Dec, 10:55 AM Solara Active Pharma - Quaterly Results 21 Oct, 2:29 PM Solara Active Pharma - Quaterly Results 21 Oct, 2:29 PM Solara Active Pharma - Quaterly Results 21 Oct, 2:29 PM Solara Active Pharma Sciences informs about voting results 24 Sep, 10:18 AM Solara Active Pharma Sciences informs about disclosure 30 Aug, 4:56 PM Solara Active Pharma Sciences informs about press release 26 Aug, 5:22 PM Solara Active Pharma Sciences informs about loss of share certificate 9 Aug, 5:11 PM Solara Active Pharma Sciences informs about monitoring agency report 29 Jul, 5:21 PM Solara Active Pharma Sciences’ consolidated net loss narrows to Rs 13 crore in Q1 22 Jul, 6:32 PM Solara Active Pharma - Quaterly Results 22 Jul, 2:02 PM Solara Active Pharma - Quaterly Results 22 Jul, 2:02 PM Solara Active Pharma - Quaterly Results 22 Jul, 2:02 PM Solara Active Pharma Sciences informs about board meeting 15 Jul, 5:01 PM Solara Active Pharma Sciences informs about analyst meet 15 Jul, 3:27 PM Solara Active Pharma Sciences informs about compliance certificate 15 Jul, 12:51 PM Solara Active Pharma Sciences informs about newspaper advertisement 24 Jun, 5:29 PM Solara Active Pharma Sciences informs about allotment 19 Jun, 12:19 PM Solara Active Pharma Sciences informs about press release 12 Jun, 2:15 PM Solara Active Pharma Sciences informs about disclosure 11 Jun, 10:47 AM Solara Active Pharma - Quaterly Results 29 May, 3:36 PM USFDA inspects Solara Active Pharma Sciences’ Visakhapatnam Facility 20 May, 11:50 AM Solara Active Pharma Sciences informs about press release 20 May, 11:06 AM Solara Active Pharma Sciences sells 100% stake in SeQuent Penems 26 Apr, 9:46 AM Solara Active Pharma Sciences gets nod to sell 100% stake in SeQuent Penems 26 Mar, 9:49 AM Solara Active Pharma Sciences informs about appointment of CFO 8 Mar, 4:13 PM Solara Active Pharma Sciences informs about notice of postal ballot 8 Mar, 12:34 PM Solara Active Pharma Sciences informs about transcript of conference call 21 Feb, 12:21 PM

Solara Active Pharma Stock Price Analysis and Quick Research Report. Is Solara Active Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Solara Active Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Solara Active Pharma has a PE ratio of 147.036053970361 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Solara Active Pharma has ROA of -0.0472% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Solara Active Pharma has a Current ratio of 0.7767.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Solara Active Pharma has a ROE of -0.1065%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Solara Active Pharma has a Debt to Equity ratio of 0.7101 which means that the company has low proportion of debt in its capital.

  • Sales growth: Solara Active Pharma has reported revenue growth of -0.4003% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Solara Active Pharma for the current financial year is 15.8783573253568%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Solara Active Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Solara Active Pharma is Rs 4.521. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Solara Active Pharma in Ticker for free. Also, one can get the intrinsic value of Solara Active Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Solara Active Pharma FAQs

Q1. What is Solara Active Pharma share price today?
Ans: The current share price of Solara Active Pharma is Rs 664.75.

Q2. What is the market capitalisation of Solara Active Pharma?
Ans: Solara Active Pharma has a market capitalisation of Rs 3200.972203925 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Solara Active Pharma?
Ans: The PE ratio of Solara Active Pharma is 147.036053970361 and the P/B ratio of Solara Active Pharma is 2.88024797646061, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Solara Active Pharma share?
Ans: The 52-week high share price of Solara Active Pharma is Rs 882.8, and the 52-week low share price of Solara Active Pharma is Rs 442.8.

Q5. Does Solara Active Pharma pay dividends?
Ans: Currently, Solara Active Pharma does not pay dividends. Dividend yield of Solara Active Pharma is around 0%.

Q6. What are the face value and book value of Solara Active Pharma shares?
Ans: The face value of Solara Active Pharma shares is Rs 10, while the book value per share of Solara Active Pharma is around Rs 230.7961. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Solara Active Pharma?
Ans: Solara Active Pharma has a total debt of Rs 776.06 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Solara Active Pharma?
Ans: The ROE of Solara Active Pharma is -0.1065% and ROCE of Solara Active Pharma is 5.9715%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Solara Active Pharma a good buy for the long term?
Ans: The Solara Active Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Solara Active Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Solara Active Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Solara Active Pharma’s financials?
Ans: You can review Solara Active Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Solara Active Pharma
X